RESUMEN
Elemene, derived from Curcuma wenyujin, one of the "8 famous genuine medicinal materials of Zhejiang province," exhibits remarkable antitumor activity. It has gained wide recognition in clinical practice for effectiveness on tumors. Dr. XIE Tian, introduced the innovative concept of "molecular compatibility theory" by combining Chinese medicine principles, specifically the "monarch, minister, assistant, and envoy" theory, with modern biomedical technology. This groundbreaking approach, along with a systematic analysis of Chinese medicine and modern biomedical knowledge, led to the development of elemene nanoliposome formulations. These novel formulations offer numerous advantages, including low toxicity, well-defined composition, synergistic effects on multiple targets, and excellent biocompatibility. Following the principles of the "molecular compatibility theory", further exploration of cancer treatment strategies and methods based on elemene was undertaken. This comprehensive review consolidates the current understanding of elemene's potential antitumor mechanisms, recent clinical investigations, advancements in drug delivery systems, and structural modifications. The ultimate goal of this review is to establish a solid theoretical foundation for researchers, empowering them to develop more effective antitumor drugs based on the principles of "molecular compatibility theory".
Asunto(s)
Antineoplásicos , Medicamentos Herbarios Chinos , Neoplasias , Sesquiterpenos , Humanos , Estudios Retrospectivos , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Neoplasias/tratamiento farmacológico , Medicamentos Herbarios Chinos/farmacología , Medicamentos Herbarios Chinos/uso terapéutico , Sesquiterpenos/farmacología , Sesquiterpenos/uso terapéuticoRESUMEN
Traditional Chinese medicine (TCM) has been recognized worldwide as a valuable asset of human medicine. The procedure of TCM is to treatment based on syndrome differentiation. However, the effect of TCM syndrome differentiation relies heavily on the experience of doctors. The gratifying progress of machine learning research in recent years has brought new ideas for TCM syndrome differentiation. In this paper, we propose a deep network model for TCM syndrome differentiation, which improves network performance by injecting TCM syndrome differentiation knowledge in the form of first-order logic into the deep network. Experimental results show that the accuracy of our proposed model reaches 89%, which is significantly better than the deep learning model MLP and other traditional machine learning models. In addition, we present the collected and formatted TCM syndrome differentiation (TSD) dataset, which contains more than 40,000 TCM clinical records. Moreover, 45 symptoms (""), 322 patterns(""), and more than 500 symptoms are labeled in TSD respectively. To the best of our knowledge, this is the first TCM syndrome differentiation dataset labeling diseases, syndromes and pattern. Such detailed labeling is helpful to explore the relationship between various elements of syndrome differentiation.
Asunto(s)
Aprendizaje Automático , Medicina Tradicional China , Humanos , Diagnóstico Diferencial , Medicina Tradicional China/métodosRESUMEN
Natural products are essential sources of antitumor drugs. One such molecule, ß-elemene, is a potent antitumor compound extracted from Curcuma wenyujin. In the present investigation, a series of novel 13,14-disubstituted nitric oxide (NO)-donor ß-elemene derivatives were designed, with ß-elemene as the foundational compound, and subsequently synthesized to evaluate their therapeutic potential against leukemia. Notably, the derivative labeled as compound 13d demonstrated a potent anti-proliferative activity against the K562 cell line, with a high NO release. In vivo studies indicated that compound 13d could effectively inhibit tumor growth, exhibiting no discernible toxic manifestations. Specifically, a significant tumor growth inhibition rate of 62.9% was observed in the K562 xenograft tumor mouse model. The accumulated data propound the potential therapeutic application of compound 13d in the management of leukemia.
Asunto(s)
Leucemia , Sesquiterpenos , Humanos , Ratones , Animales , Línea Celular Tumoral , Donantes de Óxido Nítrico/farmacología , Sesquiterpenos/farmacología , Leucemia/tratamiento farmacológico , Bioensayo , Proliferación CelularRESUMEN
This study aimed to design and synthesize active hybrids of ß-elemene and nitric oxide (NO) donor pharmacophore as potential agents for treating leukemia. Derivatives reported herein exerted better inhibitory effects against human chronic myeloid leukemia K562 cells compared to ß-elemene (IC50 > 100 µM). The most potent compound 18f showed an IC50 value of 0.53 µM against K562 cells, as well as a high NO release level in vitro. In the K562 xenograft tumor mice model, compound 18f effectively inhibited the growth of the tumor, with a significant inhibition rate of 73.18%. After treatment with compound 18f, the body weight of mice did not decrease, indicating that it possessed good safety profile. All these proved that compound 18f was an excellent potential agent against leukemia.